Literature DB >> 11430924

"Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium.

B M Dumotier1, M Bastide, M M Adamantidis.   

Abstract

Repercussions of cisapride-induced blocking effects on repolarisation of K(+) channels in open and inactivated states investigated in rabbit ventricular myocardium during rest and under stimulation were compared with effects of K(+)-blocking drugs (4-aminopyridine, dofetilide, terikalant). Major lengthening in the first postrest action potential indicates affinity for closed channels. Gradual lengthening during stimulation implies affinity for open channels. Four (control, add-in, steady-state, washout) 20-min rest periods were alternated with regular stimulation (0.5 Hz). Each drug was added during add-in and steady-state periods. Similarly to dofetilide (10 nM) and terikalant (0.3 microM), cisapride (1 microM) increasingly lengthened action potentials during stimulation, whereas 4-aminopyridine (1 mM) prolonged mostly the first postrest action potential. Our results indicate that cisapride induced use-dependent lengthening of repolarisation, compatible with an affinity for open K(+) channels. We also found that in isolated rabbit ventricular myocytes, cisapride (1-10 microM) decreased the inward rectifier K(+) current, an effect contributing to the proarrhythmic potential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430924     DOI: 10.1016/s0014-2999(01)01062-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Extracellular recordings of field potentials from single cardiomyocytes.

Authors:  Norbert Klauke; Godfrey L Smith; Jon Cooper
Journal:  Biophys J       Date:  2006-07-14       Impact factor: 4.033

2.  Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance.

Authors:  Michael Perrio; Simon Voss; Saad A W Shakir
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.